Insider Selling: Odonate Therapeutics, Inc. (NASDAQ:ODT) Major Shareholder Sells 200,000 Shares of Stock

Odonate Therapeutics, Inc. (NASDAQ:ODT) major shareholder Boxer Capital, Llc sold 200,000 shares of the business’s stock in a transaction that occurred on Monday, November 22nd. The shares were sold at an average price of $1.55, for a total value of $310,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Boxer Capital, Llc also recently made the following trade(s):

  • On Wednesday, November 24th, Boxer Capital, Llc sold 200,000 shares of Odonate Therapeutics stock. The shares were sold at an average price of $1.57, for a total value of $314,000.00.

Shares of Odonate Therapeutics stock opened at $1.60 on Thursday. Odonate Therapeutics, Inc. has a 12-month low of $1.46 and a 12-month high of $7.10. The company has a market cap of $61.58 million, a PE ratio of -0.59 and a beta of 0.43. The business’s 50 day moving average is $2.95.

Odonate Therapeutics (NASDAQ:ODT) last announced its quarterly earnings data on Wednesday, November 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.33). On average, sell-side analysts expect that Odonate Therapeutics, Inc. will post -2.43 earnings per share for the current year.

Several institutional investors have recently made changes to their positions in the company. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Odonate Therapeutics by 3.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 124,179 shares of the company’s stock valued at $361,000 after purchasing an additional 4,170 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Odonate Therapeutics by 1.1% during the 2nd quarter. Vanguard Group Inc. now owns 968,687 shares of the company’s stock valued at $3,381,000 after purchasing an additional 10,100 shares during the last quarter. Barclays PLC lifted its holdings in Odonate Therapeutics by 139.1% during the 1st quarter. Barclays PLC now owns 19,730 shares of the company’s stock valued at $68,000 after purchasing an additional 11,477 shares during the last quarter. Wolverine Trading LLC acquired a new stake in Odonate Therapeutics during the 3rd quarter valued at $35,000. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in Odonate Therapeutics during the 2nd quarter valued at $64,000. Institutional investors own 92.04% of the company’s stock.

About Odonate Therapeutics

Odonate Therapeutics, Inc is a pharmaceutical company, which engages in the development of therapeutics that improves and extends the lives of patients with cancer. It focuses on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer.

Read More: What is dollar cost averaging (DCA)?

Insider Buying and Selling by Quarter for Odonate Therapeutics (NASDAQ:ODT)

Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.